Skip to main content
Report this ad

See also:

GRAS declarations and pump-and-dump scams: An exclusive interview with FDA

NASDAQ-traded firm Senomyx (SNMX) experienced a 26 percent stock price appreciation after media outlets mistakenly reported that its product had been approved by the FDA.
NASDAQ-traded firm Senomyx (SNMX) experienced a 26 percent stock price appreciation after media outlets mistakenly reported that its product had been approved by the FDA.
Photo by Robin Marchant/Getty Images
Report this ad